1. Elmariah, et al. Nemolizumab treatment is associated with deep and lasting skin lesion and itch responses: Results from the ARCADIA long-term-extension (LTE) study up to week 152. Presented at Fall Clinical Dermatology Conference 2026; October 8-11, 2026; Las Vegas.
2. Silverberg, et al. Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis. Presented at Fall Clinical Dermatology Conference 2026; October 8-11, 2026; Las Vegas.
3. Stander, et al. Evolution of clinical response with long-term nemolizumab therapy in prurigo nodularis: From symptom relief to improvements in sleep and quality of life (AS-4212). Presented at Fall Clinical Dermatology Conference 2026; October 8-11, 2026; Las Vegas.
4. Eichenfield, et al. Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2-11 years) with moderate-to-severe atopic dermatitis. Presented at AAD 2026; March 27-31, 2026.
5. Silverberg, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 & 2): results from two replicate double-blinded, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445-460. doi:10.1016/S0140-6736(24)01203-0.
6. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013
7. Nemluvio U.S. Prescribing Information. Available online. Accessed March 2025
8. Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed March 2025
9. Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555- 022-00782-2
10. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed March 2025.
11. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed March 2025.